Jorge Nieva
Professor of Clinical Medicine
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (39)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry (n = 251,632). Pearson’s χ2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
Year:
2025
Background Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a high recurrence rate after first-line immunotherapy or chemoimmunotherapy. The presence of a high density of tumor-infiltrating lymphocytes (TILs) in HNSCC tumors was shown to be associated with improved clinical outcomes. One-time autologous TIL cell therapy was evaluated in patients with recurrent and/or metastatic HNSCC. Methods C-145-03 ( NCT03083873 ) was a phase 2 study of TIL in patients with recurrent and/or metastatic HNSCC assigned to 1 of 4 treatment cohorts: cohort 1, non-cryopreserved TIL; cohort 2, cryopreserved lifileucel (22-day manufacturing); cohort 3, cryopreserved lifileucel (16-day manufacturing); cohort 4, cryopreserved LN-145-S1 programmed cell death protein-1 (PD-1) selected. Patients underwent tumor resection for TIL generation. After preparative non-myeloablative lymphodepletion, patients received a single infusion of TIL followed by interleukin-2 (IL-2) infusion(s). The primary endpoint was investigator-assessed objective response rate (ORR) per Response Evaluation Criteria for Solid Tumors (RECIST) V.1.1. Secondary endpoints were investigator-assessed duration of response (DOR), disease control rate (DCR), progression-free survival, overall survival, and incidence of treatment-emergent adverse events. Results Overall, 53 patients received TIL: cohort 1 (n=8), cohort 2 (n=17), cohort 3 (n=16), cohort 4 (n=12). Median age was 57 years and most patients were males (87%; 46/53) with stage IV disease (98%; 52/53). Patients had a median of two prior lines of systemic therapy; 87% (46/53) of patients had prior anti-PD-1/programmed cell death ligand-1 therapy and 72% (38/53) had prior chemotherapy. The ORR was 11% (6/53) with six patients achieving partial response (cohort 1, n=3; cohort 2, n=1; cohort 4, n=2). At median follow-up of 17.9 months, the median DOR was 7.6 months. The DCR was 76% (40/53); 64% (34/53) of patients had stable disease. The safety profile was consistent with known toxicities associated with non-myeloablative lymphodepletion and IL-2 administration. Conclusions This study demonstrated the feasibility of consistently generating sufficient TIL from HNSCC tumors. Results from this study suggest TIL cell therapy may serve as a potential treatment option for patients with HNSCC and support further development, including TIL cell therapy combined with immune checkpoint inhibitors or other agents or with other TIL products. Trial registration number NCT03083873 .
Year:
2025
Race and ethnicity affect the distribution of molecular alterations seen in patients with non–small cell lung cancer (NSCLC). Although anaplastic lymphoma kinase (ALK) alterations are known to occur in 4% to 5% of the population, data specific to the Hispanic population remain limited. This study describes the real-world incidence of ALK alterations in Hispanic patients with NSCLC treated at a large academic institution in Los Angeles, California, United States, to further elucidate the underlying factors that shape differences in mutational profiles. A total of 607 patients with NSCLC treated at Los Angeles General Medical Center (n = 172) and the University of Southern California Norris Comprehensive Cancer Center (n = 435) who received comprehensive genomic profiling were evaluated from January 2015 to June 2023. The Fisher exact test and multivariate logistic regression were incorporated for statistical analysis. Hispanic patients exhibited a higher incidence of ALK alterations (12.76%, n = 18/141) than non-Hispanic patients (5.36%, n = 23/466; P = 0.0046). Multivariate logistic regression showed that Hispanic ethnicity (HR, 2.393; 95% confidence interval, 1.115–5.092) and age at diagnosis (HR, 0.9325; 95% confidence interval, 0.9081–0.9558) were significant variables in ALK alteration incidence, and 55.81% (n = 24) of ALK alterations were initially found via comprehensive genomic profiling. This study highlights a significantly higher incidence of ALK alterations among Hispanic patients with NSCLC, emphasizing the impact of race and ethnicity on molecular alterations. Future research is required to evaluate this trend in a larger, more diverse cohort and investigate the roles of environmental factors and tumor microenvironments in influencing ALK alteration prevalence. Significance: This study identified a higher incidence of ALK alterations in Hispanic patients with NSCLC (12.76%) compared with that in non-Hispanic patients (5.36%) treated at a large academic center in Los Angeles, highlighting the impact of race on molecular alteration profiles and emphasizing the need to increase access to molecular analyses for this population. The variability in mutational alterations may be influenced by biological and environmental factors.
Year:
2025
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry ( n = 251,632). Pearson’s χ 2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (45)
Fumito Ito
Professor
University of Southern California
Suresh Ramalingam
Professor, Director of Medical Oncology
Emory University
Arthi Sridhar
Assistant Professor
University of Texas Southwestern Medical Center
David Carbone
Ohio State University Medical Center
Steven R. Grossman
University of Southern California
Sachin Pai
Assistant Professor
University of South Alabama
Niels C. Kokot
University of Southern California
Hirva Mamdani
Karmanos Cancer Institute
Stephen Liu
Associate Professor
Georgetown University School of Medicine
Enakshi Saha
Assistant Professor
University of South Carolina
Camila Lopes-Ramos
Harvard University
Misako Nagasaka
University of California Irvine School of Medicine
Yueh-Yun Chi
Research Professor
University of Southern California
Balazs Halmos
Montefiore Medical Center
Ari VanderWalde
Global Head of Clinical Trials
-
David J. Pinato
Imperial College London
Richard A. Flavell
Yale University School of Medicine
Ming Li
Professor
University of Southern California
John Quackenbush
Professor of Computational Biology and Bioinformatics
Harvard T.H. Chan School of Public Health
Brahm Segal
Chair
H Lee Moffitt Cancer Center and Research Institute
Ryutaro Kajihara
Kumamoto University
Chul Kim
Georgetown University
Misty Shields
Assistant Professor
Indiana State University
Miguel Mosteiro Lamas
Institut Català d'Oncologia
Alessio Cortellini
Imperial College London
Hisashi Harada
Virginia Commonwealth University
Sylvia Lee
Fred Hutchinson Cancer Research Center
David R. Freyer
-
Angelina Lim
University of Southern California
Hossein Borghaei
Professor and Chief, Thoracic Oncology
Fox Chase Cancer Center
Rom Leidner
-
Michael Roth
Associate Professor of Pediatrics
The University of Texas MD Anderson Cancer Center Children's Cancer Hospital
Caryn Lerman
University of Southern California
Swati Palit Deb
Professor
Virginia Commonwealth University
Eziafa Oduah
Assistant Professor
Duke University
Amin Nassar
Yale University
Robert Ferris
UPMC Endowed Professor
University of Pittsburgh School of Medicine
Ana I Velazquez
Assistant Professor
University of California, San Francisco
Junko Matsuzaki
Research Professor
University of Chicago
sumitra deb
Virginia Commonwealth University
Senthil K. Radhakrishnan
Virginia Commonwealth University
Luis E. Raez
-
Jun Zhang
Professor
University of Kansas Medical Center
ENRIQUETA FELIP
Head Thoracic Oncology Unit (After Competitive Exam)
Hospital Universitari Vall d'Hebron
Jennifer Koblinski
Assistant professor, Director Cancer Mouse Models Core
Virginia Commonwealth University
Make your next move.
Prepare your application
Review drafts before you send them.